ATOS רווח למניה בשנים עשר החודשים האחרונים Atossa

The prospects of Endoxifen in breast cancer therapy create a powerful growth impulse for Atossa Therapeutics (ATOS). The change in the rolling annual EPS clearly demonstrates this trend, with the -4.34 value showing the current figure. Partnerships with oncology centers to accelerate drug registration and flawless raw material inventory management, which eliminates any supply disruptions, further strengthen the fundamentals.

For Atossa Therapeutics (ATOS), which invests in precision cancer therapy, the trailing twelve-month net income per share reflects the efficiency of monetizing scientific developments relative to the total shares outstanding. This indicator is calculated by dividing the total net income over 12 months by the number of shares, allowing investors to assess the real return on each equity stake and the company's capital stability.